| Filed On | Filing |
|---|---|
| 19 Mar 2025 |
8-K/A: Financial Statements and Exhibits
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers |
| 20 May 2019 |
8-K/A: Other Events
THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED |
| 13 May 2019 |
8-K/A: Other Events
THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED |
| 10 Apr 2014 |
8-K/A: Financial Statements and Exhibits
Consolidated Balance Sheets as of December 31, 2013 and 2012 |
| 05 Feb 2014 |
8-K/A: Unregistered Sales of Equity Securities
Reference is made to the disclosure set forth under Item 3.02 in our Current Report filed on Form 8-K on January 30, 2014, which disclosure is incorporated herein by reference. As discussed in this earlier disclosure, in January 2014 we ... |
| 25 Nov 2013 |
8-K/A: Other Events
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PART 2 (EXPLANATORY STATEMENT) OF THIS DOCUMENT COMPRISES AN EXPLANATORY STATEMENT IN COMPLIANCE WITH SECTION 897 OF THE COMPANIES ACT 2006. THIS DOCUMENT CONTAINS DETAILS... |
| 14 Nov 2013 |
8-K/A: Other Events
On November 13, 2013, we filed a technical amendment to the joint announcement we made with Xenetic Biosciences plc (“XEN”) on November 12, 2013 regarding the terms of the recommended proposal for our Acquisition of the share capital of ... |
Loading...